Loading companies…
United States · Healthtech · AI
A critical-care monitoring platform that gives clinicians continuous urine-output data and decision support for managing fluid balance and kidney risk.
FIZE kUO measures urine output continuously and provides real-time data to clinicians treating critically ill patients. By replacing intermittent manual measurements with a continuous signal, the system helps care teams see changes in kidney function and fluid status sooner.
FIZE's platform is designed to support earlier detection of acute kidney injury and more informed fluid-management decisions in intensive care. The company says FIZE kUO has received CE Mark and UKCA certification; its broader Optima software is described as a planned platform for integrating kidney intelligence with therapeutic guidance.
| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series B | Undisclosed | Asahi Kasei Medical — LeadRapha Capital Management — Lead |